We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Organogenesis Holdings Inc (ORGO) USD0.0001 A

Sell:$5.32 Buy:$6.34 Change: $0.11 (1.91%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
Change: $0.11 (1.91%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
Change: $0.11 (1.91%)
Market closed |  Prices as at close on 24 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Organogenesis Holdings Inc. is a regenerative medicine company, which is focused on the development, manufacture, and commercialization of solutions for the wound care and surgical and sports medicine markets. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

Contact details

85 Dan Rd
United States
+1 (781) 5750775

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$742.50 million
Shares in issue:
129.13 million
United States
US dollar

Key personnel

  • Gary Gillheeney
    President, Chief Executive Officer, Director
  • David Francisco
    Chief Financial Officer
  • Patrick Bilbo
    Chief Operating Officer
  • Antonio Montecalvo
    Vice President - Health Policy and Contracting
  • Brian Grow
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.